Shares of OvaScience Inc. (NASDAQ:OVAS) saw unusually-strong trading volume on Thursday . Approximately 290,879 shares traded hands during mid-day trading, a decline of 1% from the previous session’s volume of 295,308 shares.The stock last traded at $6.38 and had previously closed at $6.09.

A number of research analysts have recently weighed in on OVAS shares. Credit Suisse Group AG restated a “sell” rating on shares of OvaScience in a report on Tuesday, July 12th. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Wednesday, August 10th. JMP Securities reiterated a “neutral” rating on shares of OvaScience in a report on Wednesday, August 10th. JPMorgan Chase & Co. dropped their price target on OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Friday, August 5th. Finally, Leerink Swann reiterated a “hold” rating and set a $7.00 price target (up from $6.00) on shares of OvaScience in a report on Sunday, May 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. OvaScience presently has an average rating of “Hold” and an average target price of $10.98.

The stock’s market cap is $224.75 million. The stock’s 50 day moving average is $5.75 and its 200 day moving average is $7.09.

OvaScience (NASDAQ:OVAS) last posted its earnings results on Thursday, August 4th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.16. The firm had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.21 million. During the same quarter last year, the company posted ($0.64) EPS. The firm’s revenue was up 530.0% on a year-over-year basis. Equities research analysts predict that OvaScience Inc. will post ($2.66) EPS for the current year.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.